In this study, we evaluated the effects of MIF deficiency in tau hyperphosphorylation using two mouse models of AD, one involving intracerebroventricular (ICV) injection of streptozotocin (2-deoxy-2-(3-methyl-3-nitrosoureido)-d-glucopyranose; STZ) into WT and Mif−/− mice, and the other being the APP/PS1 transgenic mice mated with Mif−/− mice. The gene discussed is MAPT; the disease is Alzheimer disease.